American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
The full picture of how bivalirudin is emerging as a treatment without also using glycoprotein IIb/IIIa inhibition in cases of acute coronary syndrome was painted at the Atlanta meeting by Michael Lincoff from the Cleveland Clinic.